A deficiency of free protein S, known to increase the risk of peripheral venous thrombosis, has not been well described in patients with cerebrovascular disease. In a pilot study of 35 patients with symptomatic cerebrovascular disease, using a qualitative crossed immunoelectrophoresis assay we found eight patients with a free protein S deficiency. A Laurell immunoelectrophoresis assay was used to quantify the percentage of free protein S after removal of the inactive protein S C4b-binding protein complex by precipitation with polyethylene glycol 8000. In a quantitative study of 103 patients with cerebrovascular disease, 21 had a free protein S that was <20% of the average normal total protein S concentration (normal range 20-40%); 19 had suffered cerebral infarction and the other two had suffered intracranial hemorrhage. The frequency of free protein S deficiency in this group of stroke patients was far higher than the expected prevalence in the general population. (Stroke 1989;20:1657-1661 
I n the NINCDS Stroke Data Bank, nearly 40%
of all ischemic cerebral infarcts were unexplained by the traditional mechanisms of atherosclerotic, cardioembolic, or lacunar infarction.
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The high frequency of infarcts of undetermined cause led to our investigations of disorders in the coagulation system. Conditions favoring clot formation could be precursors in the development of strokes by permitting thrombi to form in response to stimuli that ordinarily would be insufficient.
The importance of the natural anticoagulant pathway in the regulation of thrombosis is becoming better appreciated. 3 - 4 Although an association of deficiencies in protein C or protein S and venous thromboembolism is well recognized, 5 -9 little has been published on the association of such deficiencies with arterial occlusive disorders. 10 Subjects and Methods Subjects for the qualitative study were drawn from patients investigated for symptomatic cerebrovascular disease during a 7-month period begin-ning in July 1986. Patients were selected based on one of the following criteria: 1) infarction of undetermined cause, 2) more than one stroke or transient ischemic attack (TIA), or 3) age at stroke onset <40 years. Subjects for the quantitative study were drawn from patients suffering cerebral infarction or intracranial hemorrhage during the 8-month period beginning in January 1988. Since the quantitative test was part of a battery ordered for all patients evaluated for acute stroke, there were no selection criteria besides evaluation in the Neurovascular Unit, which is based on bed availability and suitability for some therapeutic intervention or clinical protocol. Approximately half of all patients with stroke at Columbia-Presbyterian Medical Center are admitted to the unit.
Strokes were classified according to the diagnostic scheme used in the Stroke Data Bank.
1 Cerebral infarcts were categorized as infarction due to largeartery atherosclerosis, lacunar infarction, infarction with tandem arterial pathology, embolism from a cardiac source, and infarction of undetermined cause. Patients with infarcts of undetermined cause had no bruit or TIA ipsilateral to the hemisphere affected by the stroke, no obvious cardiac source of embolism, and if the computed tomogram (CT scan) or angiogram showed definite findings, the interpretation of these findings did not allow reliable assignment to one of the more traditional categories.
All patients had an electrocardiogram (ECG) and head CT scan and most patients had echocardiogram, carotid duplex Doppler scan, and Holter ECG recording. High-field magnetic resonance imag-ing (MRI) and cerebral angiography were also performed as clinically indicated.
All patients had routine hematologic studies including complete blood count, platelet count, and assessments of prothrombin time and partial thromboplastin time. Results of the latter two coagulation tests in each patient were compared with a concurrent control, and abnormalities were investigated by measurement of thrombin time and concentrations of fibrinogen and fibrin split products. All patients had concentrations of protein C and antithrombin III measured, and most patients had plasminogen concentration determined. Concentrations of these substances are expressed as a percentage of the mean value in healthy individuals. No patient was taking warfarin at the time of the assay.
For the measurement of free protein S, blood samples were collected from an antecubital vein using an evacuated tube containing sodium citrate as an anticoagulant. The sample was centrifuged, and the plasma was stored at -80° C until assayed. The plasma was thawed, gently mixed, and incubated at 37° C for 60 minutes. One tenth volume of 41.25% wt : vol polyethylene glycol 8000 solution was added with rapid mixing, and the tube was immediately placed in melting ice. After 60 minutes, the precipitated protein S C4b-binding protein (C4bBP) complex was deposited by centrifugation at 10,000g for 3 minutes. The supernatant containing free protein S was transferred to a clean tube.
For the qualitative study, all subjects had crossed immunoelectrophoresis. The buffers were the same for both dimensions, 50 mM Tris-Tricine at pH 8.3. Electrophoresis of the supernatant in the first dimension was carried out for 2 hours at 15 V/cm in a submarine unit (Hoefer Scientific Instruments, San Francisco, California). Excess gel was then removed and replaced with antibody-containing agar. Electrophoresis in the second dimension was carried out overnight at 10° C at 15 V/cm. After extensive washing the precipitates were visualized by staining with Coomassie blue, and the pattern was compared with that produced by normal plasma. In normal plasma two peaks can be discerned, the faster-migrating peak being free protein S.
For the quantitative study, a Laurell "rocket" immunoelectrophoresis was developed for free protein S after separation and precipitation of bound protein S with polyethylene glycol. 11 Goat antibody against human protein S, obtained from American Diagnostica (New York, New York), was used at a concentration of 0.6% vol:vol. Five microliters of supernatant was applied to each well, and electrophoresis was carried out overnight at 10° C at 15 V/cm. After extensive washing the rockets were visualized by staining with Coomassie blue. Each run included a sample of normal plasma as a control. Results are reported as a percentage of the mean normal total protein S concentration. The normal range was 20-40% based on the plasma of 30 apparently healthy individuals. The unpaired t test was used to analyze differences in mean free protein S proportion and age in the groups of patients with and without protein S deficiency. The X 2 test was used to analyze differences in proportions between these same two groups using (k-1) degrees of freedom.
Results
In the qualitative study, 35 patients with cerebrovascular disease were studied and classified into diagnostic subtypes ( Table 1) . All of the patients with stroke had CT or MRI evidence of infarction or hemorrhage. Angiography was done in 17 of the 35 patients.
Eight of the 35 patients in the qualitative study (23%) were found to have a deficiency of free protein S (Table 2 ) by crossed immunoelectrophoresis. The median age of these eight patients was 40.5 (range 18-79) years. Five had recurrent episodes; no patient with protein S deficiency had a familial history of thromboembolism. CT demonstrated cortical infarction in five, with two of the five demonstrating hemorrhagic infarcts. MRI demonstrated recurrent cerebral sinus thrombosis in one patient and a centrum semiovale infarct in another. One patient had a normal CT scan in the setting of transient monocular blindness. One patient had sickle cell anemia. A representative crossed immunoelectrophoresis is shown, which shows a normal bound protein S peak and a decreased free protein S peak compared with the normal plasma pool (Figure 1) .
All eight patients with protein S deficiency in the qualitative study had normal prothrombin and partial thromboplastin times and platelet counts ( Table  2 ). Protein C content was low in one patient. Concentrations of antithrombin III and plasminogen (when determined) were not decreased in any of the eight patients with protein S deficiency.
The high frequency of patients with free protein S deficiency in the qualitative study prompted further investigation in a larger sample of patients after the development of a quantitative assay. The demographic characteristics and distribution of stroke subtype in the 103 patients studied by Laurell immunoelectrophoresis are shown in Table 1 . All patients had MRI or CT evidence of cerebral infarction or hemorrhage. The Laurell assay was performed 4.7±24 days (mean±SD) after hospital admission. FIGURE 
Crossed immunoelectrophoresis of bound and free protein Sfor normal plasma pool and for patient BH. Peak for free protein S is less in patient BH than in normal pool.
In the quantitative study, 21 patients (20%) were found to have a free protein S deficiency (Table 3) , defined as <20% of the mean normal total protein S concentration. The age and sex distributions in the two groups were similar; however, there were significantly more blacks among the patients with free protein S deficiency (Table 3 ). There may have been fewer lacunar infarcts in this group, but the sample size was small (Table 3 ). In the group with free protein S deficiency, "other" causes of infarction included vasculitis-related infarction in two, human immunodeficiency virus-related infarction in two, and postpartum cerebral infarction in one patient.
Discussion
Our study suggests that deficiency of free protein S occurs among persons with stroke at a frequency higher than that expected in the general population. Initially using a qualitative assay, we found that 23% of our patients from a selected cohort had a free protein S deficiency. A similar high frequency (20%) was replicated by our quantitative assay in a larger sample of acute stroke patients. Whether the association that we found will be corroborated in larger series of patients awaits further study, but for the present the possible association raises diagnos- tic and therapeutic issues of importance in the subject of acute stroke.
Free protein S enhances the inactivation of factors Va and Villa by activated protein C.
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4 Protein S is also bound to C4bBP, which is an acute-phase reactant. Deficiencies of protein S may be inherited or, unlike the other natural anticoagulants, may be acquired. 8 Since free protein S, not the bound form, functions in the activation of protein C, alterations in the free-to-bound ratio may have important consequences. 11 Concentrations of free protein S may decrease secondary to inflammatory states, which increase C4bBP concentration. An increase in the concentration of C4bBP leads to a reciprocal decrease in the amount of free protein S. A decrease in free protein S concentration may lead to overactivity of the coagulation system.
No cases of stroke have been reported associated with protein S deficiency. A few instances of cerebral hemorrhagic infarction due to spontaneous cerebral venous thrombosis have been identified in patients with protein C deficiency. 12 Stroke has been reported in women taking oral contraceptives, 13 -14 a setting in which free protein S levels have been found to be reduced. 15 Free protein S deficiency was not found in a cohort of young adults with stroke in whom the blood test was performed a mean of 36 months after the stroke. 16 However, an acquired deficiency of free protein S could prove transient, and the concentration needs to be measured closer to the time of the stroke.
The occurrence of a deficiency in any natural anticoagulant may allow thrombogenesis when only a minimal trigger is present. In a normal situation, myocardial wall or valvular abnormalities, minimal extracranial carotid atherosclerosis, and hypertensive endothelial changes may not be thrombogenic. In the presence of a deficiency in the natural anticoagulant system, however, these could become origins for clot formation and subsequent embolism. Therefore, a relative hypercoagulable state may prove important in patients with stroke of either known or unknown cause.
Prophylactic therapy in protein S-deficient patients with venous thrombosis has been accomplished with warfarin. The same approach may be appropriate in patients with protein S deficiency and stroke. Until further evidence supports the latter association, we do not advocate therapeutic intervention based solely on the finding of this deficiency.
The issues of incidence and prevalence of free protein S deficiency remain unsettled. The prevalence of protein S deficiency in an unselected population with stroke may be lower than that in our study because of the selection bias operative in our hospital-based study. The importance of the natural anticoagulant proteins has not been appreciated until recently, and the time-consuming methods to determine free protein S concentrations have not encouraged widespread testing. The development of a Laurell assay will make future testing routine, but the possible transient nature of the deficiency and the effect of poststroke acute-phase reactants add to the complexity of any epidemiologic design. Future measurements should immediately predate stroke onset, which is impractical, or be done within several hours after stroke, prior to the development of secondary acute-phase reactants.
To evaluate any association between the deficiency of free protein S and stroke, which is currently only speculative, the prevalence of the deficiency in the general population, in persons with stroke, and in control groups must first be determined. Descriptions of affected patients, the factors precipitating the condition, the natural evolution of the deficiency as assessed by serial follow-up measurements, and its modification by medications are necessary to define the association. The importance of protein S in the pathogenesis of stroke is just being studied and may be a determinant in more cases than has been realized heretofore.
